We deliver
20 years ago Onno van de Stolpe founded Galapagos together with two scientists …
… Galapagos R&D doubled in staff from 298 in December 2014 to 571 employees in December 2018 …
… In 2015 we conducted 8 clinical studies, in 2019 we plan to conduct more than 40, an increase of 400% …
… Our cash balance increased from 198.4 million euro at years’ end 2014 to 1.291 billion euro in December 2018 …
… From 68,751 average daily trading volume of ordinary shares on Euronext in 2014 to approximately 481,000 ordinary shares and ADS average daily trading volume on Euronext and Nasdaq year to date in 2019 …
… Our ambition is to deliver 6 new targets, 3 preclinical candidates and 3 proof-of-concepts a year, and 1 Phase 3 start every other year …
… To date, 12 Galapagos compounds with novel modes of action discovered by us have entered studies in patients …
… We went from 8 investment banks covering Galapagos in 2008 to 19 in 2019 …
… To date, we have 3 novel mechanisms showing promising patient results: filgotinib in multiple inflammatory diseases GLGP1690 in IPF and MOR106 in atopic dermatitis …
… In our senior management levels, 33% of our staff is female …
… On 20 June 2019 we will celebrate our 20th birthday as a company …
… In 2018, we nominated 4 new preclinical candidates, all with a novel mechanism of action …
… Our global presence extended from 4 sites in 2014 to 7 in 2018 …
… In 2019, we plan to file our first medicine for registration …
… We went from 21 nationalities in 2015 to 38 in 2018 …
… The stock price on Euronext has increased >1,000% and the market capitalization has increased from ~€62 million to ~€4.8 billion (>7,000%) from 10 May 2005 to 13 March 2019 …
… We keep delivering.